StemCell Therapy

NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cell Therapy - Technologies, Markets and Companies

http://www.reportlinker.com/p0203537/Cell-Therapy---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2011, and projected to 2021.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 278 of these are profiled in part II of the report along with tabulation of 268 alliances. Of these companies, 160 are involved in stem cells. Profiles of 69 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 52 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

CELL THERAPY -1TABLE OF CONTENTS0. Executive Summary 231. Introduction to Cell Therapy 27Introduction 27Historical landmarks of cell therapy 27Interrelationship of cell therapy technologies 29Cells and organ transplantation 29Cells and protein/gene therapy 30Cell therapy and regenerative medicine 31Cells therapy and tissue engineering 31Therapy based on cells involved in disease 32Advantages of therapeutic use of cells 32Cell-based drug delivery 33Cells as vehicles for gene delivery 33Red blood cells as vehicles for drug delivery 33Advantages of cell-based drug delivery 34Limitations of cell-based drug delivery 342. Cell Therapy Technologies 35Introduction 35Cell types used for therapy 35Sources of cells 35Xenografts 36Cell lines 36Immortalized cells 36Blood component therapy 36Therapeutic apheresis 36Leukoreduction 37Platelet therapy 37Basic technologies for cell therapy 38Cell culture 38Automated cell culture devices 38Cell culture for adoptive cell therapy 39Observation of stem cell growth and viability 39Companies involved in cell culture 39Cell sorting 41Flow cytometry 41A dielectrophoretic system for cell separation 42Adult stem cell sorting by identification of surface markers 42ALDESORTER system for isolation of stem cells 42Dynabead technology for cell sorting 42Molecular beacons for specific detection and isolation of stem cells 43Multitarget magnetic activated cell sorter 43Nanocytometry 43Scepter™ cytometer 44Companies supplying cell sorters 44Cell analysis 45Cell analyzers 45In vivo cell imaging 45Measuring cell density 46Single-cell gene expression analysis 46Preservation of cells 47Innovations in cryopreservation 47Packaging of cells 48Selective expansion of T cells for immunotherapy 48Cloning and cell therapy 49Techniques for cell manipulation 49Cell-based drug discovery 50Advantages and limitations of cell-based assays for drug discovery 50Advantages and limitations of cell-based toxicity screening 50Quality control of cells for drug discovery 51Companies involved in cell-based drug discovery 51Drug delivery systems for cell therapy 53Intravenous delivery of stem cells 53Pharmacologically active microcarriers 53Devices for delivery of cell therapy 54Artificial cells 55Applications of artificial cells 55Cell encapsulation 55Diffusion capsule for cells 56Encapsulated cell biodelivery 56Therapeutic applications of encapsulated cells 56Nitric oxide delivery by encapsulated cells 58Implantation of microencapulated genetically modified cells 58Ferrofluid microcapsules for tracking with MRI 59Companies involved in encapsulated cell technology 59Electroporation 60Gene therapy 60Cell-mediated gene therapy 61Fibroblasts 61Chondrocyte 62Skeletal muscle cells 62Vascular smooth muscle cells 63Keratinocytes 63Hepatocytes 63Lymphocytes 63Mammalian artificial chromosomes 64In vivo tracking of cells 64Molecular imaging for tracking cells 64MRI technologies for tracking cells 65Superparamagnetic iron oxide nanoparticles as MRI contrast agents 66Visualization of gene expression in vivo by MRI 66Role of nanobiotechnology in development of cell therapy 66Cell transplantation for development of organs 67Cells transplantation and tolerance 67Strategies to improve tolerance of transplanted cells 68Encapsulation to prevent immune rejection 68Prevention of rejection of xenotransplants 68Expansion of allospecific regulatory T cells 68Removal and replacement of pathogenic cells of the body 69Therapeutic leukocytapheresis 693. Stem Cells 71Introduction 71Biology of stem cells 72Embryonic stem cells 72Growth and differentiation of ESCs 72Mechanisms of differentiation of ESCs 73Chemical regulation of stem cell differentiation 73In vitro differentiation of hESCs 73SIRT1 regulation during stem cell differentiation 73Regulation of stem cell self-renewal and differentiation 74hESCs for reprogramming human somatic nuclei 74Stem cells differentiation in the pituitary gland 74Influence of microenvironment on ESCs 75Role of genes in differentiation of ESCs 75Global transcription in pluripotent ESCs 75Role of p53 tumor suppressor gene in stem cell differentiation 76Role of Pax3 gene in stem cell differentiation 76Signaling pathways and ESC genes 76Epigenetics of hESCs 77Chromatin as gene regulator for ESC development 77Comparison of development of human and mouse ESCs 78Mechanism of regulation of stem cells for regeneration of body tissues 78Role of microenvironments in the regulation of stem cells 79Regulation and regeneration of intestinal stem cells 79Parthenogenesis and human stem cells 79Uniparental ESCs 80Bone marrow stem cells 81Hematopoietic stem cells 81Role of HSCs in the immune system 83Derivation of HSCs from ESCs 83Mesenchymal stem cells 83Multipotent adult progenitor cells 85Side population (SP) stem cells 85Differentiation of adult stem cells 86Growth and differentiation of HSCs 87Signaling pathways in the growth and differentiation of HSCs 87Mathematical modeling of differentiation of HSCs 87Role of prions in self renewal of HSCs 88Sources of stem cells 88Sources of of human embryonic stem cells 88Nuclear transfer to obtain hESCs 88Direct derivation of hESCs from embryos without nuclear transfer 89Alternative methods of obtaining hESCs 90Establishing hESC lines without destruction of embryo 90Altered nuclear transfer 91Small embryonic-like stem cells 91Advantages and disadvantages of ESCs for transplantation 92Use of ESC cultures as an alternative source of tissue for transplantation 92Spermatogonial stem cells 93Amniotic fluid as a source of stem cells 94Amniotic fluid stem cells for tissue repair and regeneration 94Generation of iPS cells from AF cells 94Placenta as source of stem cells 95Amnion-derived multipotent progenitor cells 95Placenta as a source of HSCs 96Umbilical cord as a source of MSCs 96Umbilical cord blood as source of neonatal stem cells 96Cryopreservation of UCB stem cells 97UCB as source of MSCs 98Applications of UCB 98Advantages of UCB 98Limitations of the use of UCB 99Licensing and patent disputes involving UCB 100Infections following UCB transplants 100Unanswered questions about UCB transplantation 101Companies involved in UCB banking 101UCB banking in the UK 102US national UCB banking system 103Future prospects of UCB as a source of stem cells 104Induced pluripotent stem cells derived from human somatic cells 104Characteristics of iPSCs 105DNA methylation patterns of iPS cells 105iPSCs derived from oocytes through SCNT 105iPSCs derived from skin 106iPSCs derived from blood 106Use of retroviral vectors for generation of iPSCs 107Use of non-integrating viral vectors for generation of iPSCs 107Generation of clinically relevant iPSCs 108Generation of RBCs from iPSCs 109iPSCs and disease modeling 109iPSCs for patient-specific regenerative medicine 110Concluding remarks about clinical potential of iPSCs 110Induced conditional self-renewing progenitor cells 110Sources of adult human stem cells 111Adipose tissue as a source of stem cells 111Intravenous infusion of adipose tissue derived MSCs 112iPSCs derived from adult human adipose stem cells 112Regulation of adipose stem cells differentiation 112Transforming adult adipose stem cells into other cells 113Multipotent stem-like cells derived from vascular endothelial cells 113Skin as a source of stem cells 113Controlling the maturation of embryonic skin stem cells 113Epidermal neural crest stem cells 114Follicle stem cells 114Mesenchymal stem cells in skin 115Regulation of stem cells in hair follicles 115Skin-derived precursor cells 115Stem cells in teeth 116Peripheral blood stem cells 116Spleen as a source of adult stem cells 117Search for master stem cells 117Vascular cell platform to self-renew adult HSC 117Adult stem cells vs embryonic stem cells 118Biological differences between adult and embryonic stem cells 118Neural crest stem cells from adult hair follicles 118Transdifferentiation potential of adult stem cells 119Limitations of adult stem cells 120Comparison of human stem cells according to derivation 120VENT cells 121Stem cell banking 121Stem cell technologies 122Analysis of stem cell growth and differentiation 122Tracking self-renewal and expansion of transplanted muscle stem cells 122Stem cell biomarkers 122Endoglin as a functional biomarker of HSCs 123STEMPRO? EZChek? for analysis of biomarkers of hESCs 123SSEA-4 as biomarker of MSCs 123p75NTR as a biomarker to isolate adipose tissue-derived stem cells 123Neural stem cell biomarker 124Protein expression profile as biomarker of stem cells 124Real-time PCR for quantification of protein biomarkers 124Study of stem cell pathways 125Study of stem cell genes 125Gene inactivation to study hESCs 125RNAi to study gene inactivation in hESCs 126Study of ESC development by inducible RNAi 126Targeting Induced Local Lesions in Genomes 127Homologous recombination of ESCs 127Immortalization of hESCs by telomerase 127Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease 128miRNA and stem cells 128Role of miRNAs in gene regulation during stem cell differentiation 128Influence of miRNA on stem cell formation and maintenance 129Transcriptional regulators of ESCs control miRNA gene expression 129Stem cells and cloning 130Cell nuclear replacement and cloning 130Nuclear transfer and ESCs 130Cloning from differentiated cells 131Cloning mice from adult stem cells 132Creating interspecies stem cells 132Cloned cells for transplantation medicine 133Claims of cloning of hESCs 133Cytogenetics of embryonic stem cells 134Engraftment, mobilization and expansion of stem cells 135Adipogenesis induced by adipose tissue-derived stem cells 136Antisense approach for preservation and expansion of stem cells 136Biomatrials for ESC growth 137Chemoattraction of neuronal stem cells through GABA receptor 137Enhancement of HSC engraftment by calcium-sensing receptor 137Enhancement of stem cell differentiation by Homspera 138Ex vivo expansion of human HSCs in culture 138Ex vivo expansion of MSCs 139Ex vivo expansion of UCB cells for transplantation 139Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase 139Expansion of adult stem cells by activation of Oct4 140Expansion of transduced HSCs in vivo 140Expansion of stem cells in vivo by Notch receptor ligands 140Mobilization of HSCs by growth factors 140Mobilization of stem cells by cytokines/chemokines 141Mobilization of adult human HSCs by use of inhibitors 142Mobilization of stem cells by HYC750 142Mobilization of stem cells by hyperbaric oxygen 143Mobilization by adenoviral vectors expressing angiogenic factors 143Selective mobilization of progenitor cells from bone marrow 143Selective Amplification 144Stem cell mobilization by acetylcholine receptor agonists 144Use of parathyroid hormone to increase HSC mobilzation 144Technologies for inducing differentiation of stem cells 145Generation of RBCs from hematopoietic stem cells 145Generation of multiple types of WBCs from hESCs and iPSCs 145Growth factor-induced differentiation of MAPCs 145Lineage selection to induce differentiation of hESCs 146Mechanical strain to induce MSC differentiation 146Neurotrophin-mediated survival and differentiation of hESCs 146Synthetic biology and stem cells 147Use of RNAi to expand the plasticity of autologous adult stem cells 147Use of carbohydrate molecules to induce differentiation of stem cells 148Limitations of the currently available stem cell lines in the US 148Stem cell separation 148Stem cell culture 149Culture of hMSCs 150Elimination of contaminating material in stem cell culture 150Long-term maintenance of MSC multipotency in culture 151Nanofiber scaffolds for stem cell culture 152Conversion of stem cells to functioning adipocytes 152Mass production of ESCs 152Promoting survival of dissociated hESCs 153Analysis and characterization of stem cells 153Havesting and identification of EPCs 153Labeling of stem cells 154Labeling, imaging and tracking of stem cells in vivo 154Perfluorocarbon nanoparticles to track therapeutic cells in vivo 154Project for imaging in stem cell therapy research 155Quantum dots for labeling and imaging of stem cells 155Superparamagnetic iron oxide nanoparticles for tracking MSCs 156Applications of stem cells 156Commercial development and applications of adult stem cells 157Retrodifferentiation of stem cells 157MultiStem 157Controlling the maintenance process of hematopoietic stem cells 157Self renewal and proliferation of HSCs 157Aging and rejuvenation of HSCs 158Peripheral blood stem cell transplantation 158Role of stem cells in regeneration 158Promotion of regeneration by Wnt/beta-catenin signaling 159Stem cells and human reproduction 159Expansion of spermatogonial stem cells 159Conversion of ESCs into spermatogonial stem cells 159Conversion of stem cells to oocytes 160ESCs for treatment of infertility in women 160Cloning human embryos from oocytes matured in the laboratory 161In utero stem cell transplantation 161Innovations in delivery of stem cells 162Polymeric capsules for stem cell delivery 163Immunological aspects of hESC transplantation 163Immunosuppression to prevent rejection of hESC transplants 163Histocompatibility of hESCs 163Strategies for promoting immune tolerance of hESCs 164Stem cells for organ vascularization 164Activation of EphB4 to enhance angiogenesis by EPCs 165Advantages and limitations of clinical applications of MSCs 165Biofusion by genetically engineering stem cells 166Stem cell gene therapy 166Combination of gene therapy with nuclear transfer 166Gene delivery to stem cells by artificial chromosome expression 167Genetic manipulation of ESCs 167Genetic engineering of human stem cells for enhancing angiogenesis 168HSCs for gene therapy 168Helper-dependent adenoviral vectors for gene transfer in ESCs 169Lentiviral vectors for in vivo gene transfer to stem cells 169Linker based sperm-mediated gene transfer technology 169Mesenchymal stem cells for gene therapy 169Microporation for transfection of MSCs 170Regulation of gene expression for SC-based gene therapy 170Stem cells and in utero gene therapy 170Therapeutic applications for hematopoietic stem cell gene transfer 171The future of hematopoietic stem cell gene therapy 171Stem cell pharmaceutics 171Cardiomyocytes derived from hESCs 171ESCs as source of models for drug discovery 172hESC-derived hepatocytes for drug discovery 173Pharmaceutical manipulation of stem cells 173Role of stem cells in therapeutic effects of drugs 175Stem cells for drug discovery 175Stem cells for drug delivery 176Stem cell activation for regeneration by using glucocortoids 176Toxicology and drug safety studies using ESCs versus other cells 177Future challenges for stem cell technologies 179Study of the molecular mechanism of cell differentiation 179MBD3-deficient ESC line 180In vivo study of human hemopoietic stem cells 180Stem cell biology and cancer 180Research into plasticity of stem cells from adults 181Stem cells and aging 181Activation of bone marrow stem cells into therapeutic cells 182Role of nitric oxide in stem cell mobilization and differentiation 183Stem cell genes 183Gene expression in hESCs 183The casanova gene in zebrafish 184Nanog gene 184Stem cell proteomics 185hESC phosphoproteome 186Proteomic studies of mesenchymal stem cells 186Proteomic profiling of neural stem cells 186Proteome Biology of Stem Cells Initiative 187Genomic alterations in cultured hESCs 187Hybrid embryos/cybrids for stem cell research 187Generation of patient-specific pluripotent stem cells 188Markers for characterizing hESC lines 189Switch of stem-cell function from activators to repressors 189Stem cell research at academic centers 190International Regulome Consortium 191Companies involved in stem cell technologies 191Concluding remarks about stem cells 196Challenges and future prospects of stem cell research 1974. Clinical Applications of Cell Therapy 199Introduction 199Cell therapy for hematological disorders 199Transplantation of autologous hematopoietic stem cells 199Hemophilias 199Ex vivo cell/gene therapy of hemophilia B 199Cell/gene therapy of hemophilia A 200Hematopoietic stem cell therapy for thrombocytopenia 201Stem cell transplant for sickle cell anemia 201Treatment of chronic acquired anemias 202Implantation of genetically engineered HSCs to deliver rhEpo 202Drugs acting on stem cells for treatment of anemia 202Stem cell therapy of hemoglobinopathies 203Stem cells for treatment of immunoglobulin-light chain amyloidosis 203Future prospects of cell therapy of hematological disorders 203Cell therapy for immunological disorders 204Role of dendritic cells in the immune system 204Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures 204Potential of MSCs as therapy for immune-mediated diseases 205Stem cell therapy of chronic granulomatous disease 205Stem cell therapy of X-linked severe combined immunodeficiency 206Stem cell therapy of autoimmune disorders 206Treatment of rheumatoid arthritis with stem cells 206Treatment of Crohn's disease with stem cells 207Stem cell transplants for scleroderma 207Role of T Cells in immunological disorders 208Autologous T cells from adult stem cells 208Cell therapy for graft vs host disease 209MSCs for GVHD 210Cell therapy for viral infections 210T-cell therapy for CMV 210T-cell therapy for HIV infection 211T-cell immunity by Overlapping Peptide-pulsed Autologous Cells 211Anti-HIV ribozyme delivered in hematopoietic progenitor cells 212Dendritic-cell targeted DNA vaccine for HIV 212Cell therapy of lysosomal storage diseases 212Niemann-Pick disease 213Gaucher's disease 213Fabry's disease 214Cell therapy for diabetes mellitus 214Limitations of current treatment 215Limitations of insulin therapy for diabetes mellitus 215Limitations of pancreatic transplantation 215Islet cell transplantation 216Autologous pancreatic islet cell transplantation in chronic pancreatitis 216Clinical trials of pancreatic islet cell transplants for diabetes 216Drawbacks of islet cell therapy 217Use of an antioxidant peptide to improve islet cell transplantation 217Cdk-6 and cyclin D1 enhance human beta cell replication and function 218A device for delivery of therapeutic cells in diabetes 218Monitoring of islet cell transplants with MRI 218Concluding remarks about allogeneic islet transplantation for diabetes 219Encapsulation of insulin producing cells 219Encapsulated porcine pancreatic islet cells for pancreas 219Encapsulated insulinoma cells 220Magnetocapsule enables imaging/tracking of islet cell transplants 220Islet precursor cells 221Dedifferentiation of ? cells to promote regeneration 221Pharmacological approaches for ? cell regeneration 222Xenotransplantation of embryonic pancreatic tissue 222Non-pancreatic tissues for generation of insulin-producing cells 223Exploiting maternal microchimerism to treat diabetes in the child 223Bio-artificial substitutes for pancreas 223Role of stem cells in the treatment of diabetes 224Embryonic stem cells for diabetes 224HSC transplantation to supplement immunosuppressant therapy 225Human neural progenitor cells converted into insulin-producing cells 225Insulin-producing cells derived from UCB stem cells 226iPS cells for diabetes 226Isolation of islet progenitor cells 226Pancreatic progenitor cells Expansion in vitro 227Pancreatic stem cells 227Stem cell injection into portal vein of diabetic patients 227Dendritic cell-based therapy for type 1 diabetes 228Vaccine for diabetes 228Gene therapy in diabetes 228Viral vectors for gene therapy of diabetes 229Genetically engineered dendritic cells 229Genetically altered liver cells 229Genetically modified stem cells 230Companies developing cell therapy for diabetes 230Concluding remarks about cell and gene therapy of diabetes 231Cell therapy of gastrointestinal disorders 232Inflammatory bowel disease 232Cell therapy for liver disorders 233Types of cells and methods of delivery for hepatic disorders 233Bioartificial liver 234Limitations of bioartificial liver 235Stem cells for hepatic disorders 235Deriving hepatocytes from commercially available hMSCs 236Implantation of hepatic cells derived from hMSCs of adipose tissue 236MSC derived molecules for reversing hepatic failure 236Cell-based gene therapy for liver disorders 237Transplantation of genetically modified fibroblasts 237Transplantation of genetically modified hepatocytes 237Intraperitoneal hepatocyte transplantation 238Genetically modified hematopoietic stem cells 238Use of iPSCs derived from somatic cells for liver regeneration 238Clinical applications 238Future prospects of cell-based therapy of hepatic disorders 239Cell therapy of renal disorders 239Bioartificial kidney 240Cell-based repair for vascular access failure in renal disease 240Mesangial cell therapy for glomerular disease 240Stem cells for renal disease 241Role of stem cells in renal repair 241Bone marrow stem cells for renal disease 241MSC therapy for renal disease 242Cell therapy for pulmonary disorders 242Delivery of cell therapy for pumonary disorders 242Intratracheal injection of cells for pulmonary hypoplasia 242Role of stem cells in pulmonary disorders 243Lung stem cells 243Lung tissue regeneration from stem cells 243Role of stem cells in construction of the Cyberlung 244Respiratory epithelial cells derived from UCB stem cells 244Respiratory epithelial cells derived from hESCs 244Lung tissue engineering with adipose stromal cells 245Cell-based tissue-engineering of airway 245Pulmonary disorders that can be treatable with stem cells 245Acute lung injury and ARDS treated with MSCs 246Bronchopulmonary dysplasia treated with MSCs 247Chronic obstructive pulmonary disease treated with MSCs 247Cystic fibrosis treatment with genetically engineered MSCs 247Lung regeneration by integrin ?6?4-expressing alveolar epithelial cell 248Pulmonary arterial hypertension treatment with EPCs 248Cell therapy for disorders of bones and joints 249Repair of fractures and bone defects 249Adult stem cells for bone grafting 250Cell therapy for osteonecrosis 250Cell therapy for cervical vertebral interbody fusion 250ESCs for bone repair 251Intrauterine use of MSCs for osteogenesis imperfecta 251In vivo bone engineering as an alternative to cell transplantation 251MSCs for repair of bone defects 251MSCs for repair of bone fractures 254Osteocel 255Stem cells for repairing skull defects 255Stem cell-based bone tissue engineering 255Spinal fusion using stem cell-based bone grafts 256Osteoarthritis and other injuries to the joints 257Mosaicplasty 257Autologous cultured chondrocytes 257Autologous intervertebral disc chondrocyte transplantation 258Cartilage repair by genetically modified fibroblasts expressing TGF-? 259Generation of cartilage from stem cells 260Role of cell therapy in repair of knee cartilage injuries 261Role of cells in the repair of anterior cruciate ligament injury 263Autologous tenocyte implantation in rotator cuff injury repair 263Platelet injection for tennis elbow 264Cell therapy of rheumatoid arthritis 264Cell therapy for diseases of the eye 265Cell therapy for corneal repair 265Stem cell therapy for limbal stem cell deficiency 266Role of stem cells in fibrosis following eye injury 267Stem cell transplantation for radiation sickness 267MSCs for treatment of radiation damage to the bone 267MSCs for regeneration of ovaries following radiotherapy damage 268Cell therapy for regeneration 268Stem cells for regenerating organs 268Umbilical cord blood for regeneration 269Role of stem cells in regeneration of esophageal epithelium 269Cell therapy for regeneration of muscle wasting 269Wound healing: skin and soft tissue repair 270Cells to form skin substitutes for healing ulcers 271CellSpray for wound repair 271Cell therapy for burns 272Closure of incisions with laser guns and cells 273Follicular stem cells for skin and wound repair 273Reprogramming autologous stem cells for wound regeneration 274Role of amniotic fluid MSCs in repair of fetal wounds 274Genetically engineered keratinocytes for wound repair 274MSCs for wound healing 275Regeneration of aging skin by adipose-derived stem cells 275Repair of aging skin by injecting autologous fibroblasts 275Role of cells in tissue engineering and reconstructive surgery 275Stem cells for tissue repair 275Scaffolds for tissue engineering 276Improving vascularization of engineered tissues 276Enhancing vascularization by combining cell and gene therapy 277Choosing cells for tissue engineering 277ESCs vs adult SCs for tissue engineering 277Use of adult MSCs for tissue engineering 278Nanobiotechnology applied to cells for tissue engineering 279Stem cells for tissue engineering of various organs 279Engineering of healthy living teeth from stem cells 279Adipose tissue-derived stem cells for breast reconstruction 280Improving tissue engineering of bone by MSCs 281Intra-uterine repair of congenital defects using amniotic fluid MSCs 281Cell-based tissue engineering in genitourinary system 282Urinary incontinence 282Tissue engineering of urinary bladder 283Label retaining urothelial cells for bladder repair 283MSCs for bladder repair 284Tissue-engineering of urethra using autologous cells 284Repair of the pelvic floor with stem cells from the uterus 284Reconstruction of vagina from stem cells 285Facial skin regeneration by stem cells as an alternative to face transplant 285Reconstruction of cartilage for repair of craniofacial defects 285Cell therapy for rejuvenation 286Cell therapy for performance enhancement in sports 286Application of stem cells in veterinary medicine 286Use of stem cells to repair tendon injuries 286Stem cells for spinal cord injury in dogs 2875. Cell Therapy for Cardiovascular Disorders 289Introduction to cardiovascular disorders 289Limitations of current therapies for myocardial ischemic disease 289Types of cell therapy for cardiovascular disorders 289Cell-mediated immune modulation for chronic heart disease 290Human cardiovascular progenitor cells 291Inducing the proliferation of cardiomyocytes 291Pericardial origin of colony-forming units 292Role of the SDF-1-CXCR4 axis in stem cell therapies for myocardial ischemia 292Role of splenic myocytes in repair of the injured heart 292Reprogramming of fibroblasts into functional cardiomyocytes 293Small molecules to enhance myocardial repair by stem cells 293Cell therapy for atherosclerotic coronary artery disease 293MyoCell™ (Bioheart) 294Cardiac stem cells 294Cardiomyocytes derived from epicardium 295Methods of delivery of cells to the heart 296Cellular cardiomyoplasty 296IGF-1 delivery by nanofibers to improve cell therapy for MI 296Non-invasive delivery of cells to the heart by Morph®guide catheter 296Cell therapy for cardiac revascularization 297Transplantation of cardiac progenitor cells for revascularization of myocardium 297Stem cells to prevent restenosis after coronary angioplasty 297Role of cells in cardiac tissue repair 298Modulation of cardiac macrophages for repair of infarct 298Transplantation of myoblasts for myocardial infarction 298Patching myocardial infarction with fibroblast culture 299Cardiac repair with myoendothelial cells from skeletal muscle 299Myocardial tissue engineering 300Role of stem cells in repair of the heart 301Role of stem cells in cardiac regen

To order this report:Biological Therapy Industry: Cell Therapy - Technologies, Markets and Companies

More  Market Research Report

Check our  Industry Analysis and Insights

 

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

Go here to see the original:
Cell Therapy - Technologies, Markets and Companies

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment.

The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency.

Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday.

The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual.

The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease.

Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs safer and mean fewer adverse drug reactions, and reduce costs to health-care systems.

"The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health-care system and even save costs in certain circumstances," Aglukkaq said in a news release.

Research projects could last four years

The sequencing of the human genome paved the way for personalized medicine and there have been calls for more research funding so that the discoveries in laboratories can be translated further into the medical field so they will benefit patients more.

Identifying a person's genetic profile, for example, could then indicate a susceptibility to a certain disease, if the biomarkers of that disease have also been discovered. If people know they are genetically at risk of an illness they can take actions to prevent it, and their health-care providers can monitor for it.

Cancer patients could be pre-screened to determine if chemotherapy would work for them, which could not only save a lot of money on expensive treatments but also prevent pain and suffering for patients.

Genome Canada is leading the research initiative, in collaboration with Cancer Stem Cell Consortium and CIHR which on Tuesday launched its Personalized Medicine Signature Initiative. CIHR is committing up to $22.5 million to the large-scale initiative with the other two partners, but it will be providing more funding for other projects under its personalized medicine program.

The research projects are aiming to bring together biomedical, clinical, population health, health economics, ethics and policy researchers to identify areas that are best suited to personalized medicine.

Oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease are all considered to be areas that hold promise for personalized medicine.

Funding will also go to projects that are aimed at developing more evidence-based and cost-effective approaches to health care.

Researchers can get up to four years of funding, but 50 per cent of their requested funding must be matched from another source, such as a provincial government or from the academic or private sectors.

Genome Canada, CIHR and the cancer consortium will invest a maximum of $5 million in each individual project.

The successful applicants for the $67.5 million worth of funding won't be announced until December.

Continue reading here:
'Personalized medicine' gets $67.5M research boost

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology,
Inc. (“ACT”;
OTCBB: ACTC), a leader in the field of regenerative
medicine, announced today that the Aberdeen Royal Infirmary,
the largest of the Grampian University Hospitals in Scotland,
has been confirmed as a site for its Phase 1/2 human clinical
trial for Stargardt’s Macular Dystrophy (SMD) using retinal
pigment epithelial (RPE) cells derived from human embryonic
stem cells (hESCs). The Phase 1/2 trial is a prospective,
open-label study designed to determine the safety and
tolerability of the RPE cells following sub-retinal
transplantation into patients with SMD.

“A leading medical institution in the United Kingdom, Aberdeen
Royal Infirmary is an ideal partner for our European clinical
trial for SMD,” said Gary Rabin, chairman and CEO of ACT.
“Moreover, we are particularly pleased that the lead
investigator is Dr. Noemi Lois, a leading expert in SMD. We
continue to forge ties with some of the best eye surgeons and
hospitals in the world and work towards bringing this
cutting-edge therapy closer to fruition. Our preliminary
results to date keep us optimistic that we are on the right
path both in terms of our science and the clinical team we are
working with, particularly eye surgeons such as Dr. Lois.”

Stargardt's Macular Dystrophy affects an estimated 80,000 to
100,000 patients in the U.S. and Europe, and causes progressive
vision loss, usually starting in people between the ages of 10
to 20, although the disease onset can occur at any age.
Eventually, blindness results from photoreceptor loss
associated with degeneration in the pigmented layer of the
retina, the retinal pigment epithelium. “The first Stargardt’s
patient to be treated in the U.S. with stem cell-derived RPE
cells was a patient who was already legally blind as a
consequence of this disease” stated Dr. Robert Lanza M.D., the
chief scientific officer at ACT. Preliminary results from the
treatment of the first SMD patient were recently
reported in
The Lancet (23 January 2012) and have been
characterized by experts in the field of regenerative medicine
as providing early signs of safety and efficacy.

This approved SMD clinical trial that Dr. Lois and her team
will participate in is a prospective, open-label study designed
to determine the safety and tolerability of RPE cells derived
from hESCs following sub-retinal transplantation to patients
with advanced SMD, and is similar in design to the FDA-cleared
US trial initiated in July 2011.

“It is an honor to have been designated as a site for this
path-breaking clinical trial,” said Noemi Lois, M.D., Ph.D. “We
could not be more pleased to be a part of this trial for a
promising potential new treatment for SMD, using hESC-derived
RPE cells.” Dr. Lois is a is a member of the Department of
Ophthalmology, NHS Grampian, and associated to the University
of Aberdeen, Scotland, United Kingdom. Dr. Lois practices at
the Aberdeen Royal Infirmary; she is an Ophthalmologist with
special interest in Medical retina and Retinal surgery.

On January 23, 2012, the company
announced that the first patient in this SMD clinical trial
in Europe had been treated at Moorfields Eye Hospital in
London.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company
applying cellular technology in the field of regenerative
medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial
and operating results, future growth in research and
development programs, potential applications of our technology,
opportunities for the company and any other statements about
the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform
Act of 1995. Any statements that are not statements of
historical fact (including statements containing the words
“will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered
to be forward-looking statements. There are a number of
important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for
future capital, risks inherent in the development and
commercialization of potential products, protection of our
intellectual property, and economic conditions generally.
Additional information on potential factors that could affect
our results and other risks and uncertainties are detailed from
time to time in the company’s periodic reports, including the
report on Form 10-K for the year ended December 31, 2010.
Forward-looking statements are based on the beliefs,
opinions, and expectations of the company’s management at the
time they are made, and the company does not assume any
obligation to update its forward-looking statements if those
beliefs, opinions, expectations, or other circumstances should
change. Forward-looking statements are based on the beliefs,
opinions, and expectations of the company’s management at the
time they are made, and the company does not assume any
obligation to update its forward-looking statements if those
beliefs, opinions, expectations, or other circumstances should
change. There can be no assurance that the Company’s clinical
trials will be successful.

See the rest here:
ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ...

NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:

Biobanking for Medicine: Technology and Market
2012-2022

http://www.reportlinker.com/p0765582/Biobanking-for-Medicine-Technology-and-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Report Details

What does the future hold for biobanks? Visiongain's report
shows you potential revenues and trends to 2022. Find data,
forecasts and discussions for biobanking in medicine.

Discover sales predictions at overall market, submarket and
national levels to 2022. Our study gives you business research,
analysis and opinion for applications in medical research,
pharmaceuticals and diagnostics. 

How will the biobanking industry perform? Receive forecasts for
human tissue banking, stem cell banking, private cord banking,
other services (e.g., DNA and RNA storage), commercial
biobanks, academic collections and other operations. You find
revenues and discussions.

R&D applications are multiplying and widening. Assess
contributions of biobanks in understanding disease, drug
discovery, drug development and biomarkers. This decade will
result in technological and organisational progress, public and
private, benefiting healthcare. 

Our report discusses Cryo-Cell International, Cord Blood
America, Tissue Solutions, Asterand,
ViaCord, LifebankUSA, China Cord Blood and other
organisations. See activities and outlooks. 

Biobanks and biorepositories will become more important to
medical R&D and human healthcare. Biological science and
technology stand to benefit. Discover the prospects. 

Visiongain's study provides data, analysis and opinion aiming
to help your research, calculations, meetings and
presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends,
discussions and interviews

In the report you find revenue forecasting, growth rates,
market shares, qualitative analyses (incl. SWOT and STEP), news
and views. You receive 72 tables and charts and six research
interviews.

Advantages of Biobanking for Medicine: Technology and
Market 2012-2022 for your work

In particular, this study gives you the following knowledge and
benefits:• Find revenue predictions to 2022 for the overall
world market and submarkets, seeing growth trends• Assess
companies in medical biobanking, discovering activities and
outlooks• See revenue forecasts to 2022 in leading countries
for human tissue banking -
US, Japan, Germany,France, UK, Spain, Italy, China and India•
Review developmental trends for biobanks - technologies and
services• Investigate competition and opportunities influencing
commercial results• Find out what will stimulate and restrain
that industry and market• View expert opinions from our survey
of that biotechnology sector.

There, you receive a distinctive mix of quantitative and
qualitative work with independent predictions. We analyse
developments and prospects, helping you to stay ahead.

Gain business research, data and analysis for medical
biobanking Our study is for everybody needing industry
and market analyses for medical biobanks. Find data, trends and
answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal
GovernmentCCR Ref number: KD4R6 

Table of Contents1. Executive Summary

1.1 Summary Points of this Report

1.2 Aims, Scope and Format of the Report

1.2.1 Speculative Aspects of Assessing the Biobanking Market

1.2.2 Chapter Outlines

1.3 Research and Analysis Methods

1.3.1 Human Tissue Banking Market

1.3.2 Stem Cell Banking Market

2. Introduction to Biobanking2.1 Biobanking2.1.1 Processes
Involved in Biobanking2.2 Biobanks: A Two-Fold Character2.3 Key
Features2.4 Classification of Biobanks2.4.1 Volunteer
Groups2.4.1.1 Population-Based Biobanks2.4.1.2 Disease-Oriented
Biobanks2.4.2 Ownership or Funding Structure2.5 Guidelines and
Standards2.5.1 Guidelines for Biobanks and Use of Biological
Samples for Research2.5.2 Industry Standards for Biobanks2.5.3
Biobanking Processes Governed by Guidelines2.6 Laws and
Regulations for Biobank-Based Research

3. Biobanking and the Pharmaceutical Industry

3.1 Scientific and Commercial Use of Biobanking in the
Pharmaceutical Industry

3.1.1 Research and Drug Development

3.1.1.1 Understanding Disease Pathways

3.1.1.2 Drug Discovery

3.1.1.3 Biomarker Discovery

3.1.2 Therapeutics

3.1.3 Clinical Trials

3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking Associated Market: Systems, Software, Consumables
and Services Associated with Biobanking4.1 Overview4.2
Systems/Technologies4.2.1 Automated Liquid Handling4.2.1.1
Frozen Aliquotting: New Technology in Development4.2.2
Storage4.2.2.1 Ultra-Low Temperature Freezing4.2.2.2
Room-Temperature Storage4.2.3 RFID and Tagging Technologies4.3
Software4.3.1 Laboratory Information Management System
(LIMS)4.3.1.1 LIMS Functions4.4 Consumables4.5 Services

5. The World Medical Biobanking Market to 2022

5.1 Current State of the Biobanking Market

5.2 Geographical Footprint

5.3 Growing Demand for Biobank Resources

5.4 Revenue Forecast for Overall Market

5.4.1 Scope and Limitations

5.4.2 Biobanking Market, 2011-2022

5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016

5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022

5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market6.1 Revenue Forecast for Overall
Human Tissue Banking Market, 2011-20226.1.1 Revenue Forecast
for Overall Human Tissue Banking Market, 2011-20166.1.2 Revenue
Forecast for Overall Human Tissue Banking Market, 2017-20226.2
Revenue Forecasts for Human Tissue Banking Market by Type of
Biobank, 2011-20226.2.1 Revenue Forecast for Commercial Human
Tissue Banking Market, 2011-20166.2.2 Revenue Forecast for
Commercial Human Tissue Banking Market, 2017-20226.2.3 Revenue
Forecast for Academic & Other Human Tissue Banking Market,
2011-20166.2.4 Revenue Forecast for Academic & Other Human
Tissue Banking Market, 2017-20226.3 Revenue Forecasts for Human
Tissue Banking in Leading National Markets, 2011-20226.4 Some
Commercial Participants in the Human Tissue Banking Market6.4.1
Business Models of Companies in the Biobanking Market6.4.2
Tissue Solutions6.4.2.1 Overview6.4.2.2 Global Presence6.4.2.3
Products and Services6.4.2.3.1 Banked Samples6.4.2.3.2
Prospective Samples6.4.2.3.3 Fresh Samples6.4.2.3.4 Freshly
Isolated and Primary Cells6.4.2.3.5 Services6.4.2.4 Strengths
and Capabilities6.4.2.5 Future Outlook6.4.3 Asterand6.4.3.1
Overview6.4.3.2 Global Presence6.4.3.3 Products and
Services6.4.3.3.1 XpressBANK6.4.3.3.2 ProCURE6.4.3.3.3
PhaseZERO6.4.3.3.4 BioMAP6.4.3.4 Asterand: Raised Barriers for
New Market Entrants?6.4.3.5 Financial Performance6.4.3.6 Future
Outlook

7. Stem Cell Banking

7.1 Overview

7.2 Revenue Forecast for Overall Stem Cell Banking Market,
2011-2022

7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016

7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022

7.3 Stem Cell Banks for Research: High Growth Possible

7.4 Umbilical Cord Blood Banking for Stem Cells

7.4.1 Blood Banks: Private vs. Public

7.4.2 Biological Insurance: Private Blood Banking

7.4.3 Umbilical Cord Banking: The Controversies

7.4.3.1 US Oversight of Cord Blood Stem Cells

7.4.4 Revenue Forecast for Private Cord Blood Banking Market,
2011-2016

7.4.5 Revenue Forecast for Private Cord Blood Banking Market,
2017-2022

7.4.6 Companies in the Field

7.4.6.1 Cord Blood America: Looking Towards the Chinese
Market

7.4.6.2 ViaCord: 145,000 Blood Units in Storage

7.4.6.3 Cryo-Cell International: The First Cord Blood Bank

7.4.6.4 Stem Cell Authority: Exclusive Stem Cells

7.4.6.5 LifebankUSA: Placenta-Cord Banking

7.4.6.6 Biogenea-Cellgenea

7.4.6.7 China Cord Blood Corp

7.4.6.8 Cryo-Save

7.4.6.9 Thermogenesis

7.5 Gene/DNA Banking

8. Industry Trends8.1 Automated Biobanking8.1.1 Increased
Uptake of Laboratory Information Management Systems (LIMS) in
Biobanking8.1.2 Addressing Sample Storage and Tracking
Issues8.2 Green Banking8.3 Creation of National Biobanks8.4
HIPAA Amendments

9. Qualitative Analysis of the Biobanking Sector

9.1 Strengths

9.1.1 Wealth of Information for Genetic Research

9.1.2 Potential to Change Treatments

9.1.3 Many Governments Support Biobanking

9.2 Weaknesses

9.2.1 Quality Concerns for Some Existing Biospecimen
Collections

9.2.2 Lack of Standardisation and Harmonisation of Best
Practices

9.2.3 Limited Sharing and Linkage of Biobanks

9.3 Opportunities

9.3.1 Genome-Wide Association Studies (GWAS)

9.3.2 Personalised Medicine

9.3.3 Pharmacogenomics: Driving the Personalised Medicine
Approach

9.4 Threats

9.4.1 Ethical and Regulatory Issues

9.4.1.1 Limitations of Informed Consent in Biobanking

9.4.1.2 Confidentiality and Security to Prevent Improper Use

9.4.2 Social and Cultural Issues

9.4.3 Ownership Issues

9.4.4 Funding

10. Research Interviews from Our Survey10.1 Dr Morag McFarlane,
Chief Scientific Officer, Tissue Solutions10.1.1 On the Use of
Biobank Samples in the Pharmaceutical Industry 10.1.2 On
Commercial Aspects of Biobanking10.1.3 On the Business of
Tissue Solutions10.1.4 On the Attractiveness of Human Tissue
Banking10.1.5 On the Future of the Biobanking Market10.2 Dr
Angel García Martín, Director, Inbiomed10.2.1 On the Importance
of Biobanking in the Pharmaceutical Industry 10.2.2 On the
Use of Technology in Biobanking 10.2.3 On Increased
Recognition of Biobanking and Harmonisation of
Samples 10.2.4 On the Use of Biobanks by the
Pharmaceutical Industry 10.2.5 On Private Biobanks and
Scale of Operations 10.2.6 On Commercial and Public
Biobanking and Legislation 10.2.7 On the Most Attractive
Segment in Commercial Biobanking10.2.8 On the Future of
Biobanking: Drivers and Challenges10.3 Dr Piet Smet, Director,
Business Development, BioStorage Technologies10.3.1 On Defining
Biorepositories and Biobanks10.3.2 On the Services of
Biostorage10.3.3 On Main Customers for Biostorage10.3.4 On the
Importance of Biorepositories in Research and Industry10.3.5 On
Technology Use in Biobanks10.3.6 On Increased Recognition of
Biobanking and Harmonisation of Samples 10.3.7 On the Use
of Biobanks by the Pharmaceutical Industry 10.3.8 On
Private Biobanks and Scale of Operations 10.3.9 On
Commercial and Public Biobanking and Legislation 10.3.10
On the Most Attractive Segment in Commercial Biobanking10.3.11
On Biobanking in 202010.3.12 On Drivers and Challenges in the
Sector10.4 Dr Tom Hoksbergen, Marketing and Sales,
SampleNavigator Laboratory Automation Systems10.4.1 On the
Services of SampleNavigator10.4.2 On Main Customers for
SampleNavigator10.4.3 On the Importance of Biorepositories in
Research and Industry10.4.4 On Technology Use in Biobanks10.4.5
On Increased Recognition of Biobanking and Harmonisation of
Samples 10.4.6 On the Use of Biobanks by the
Pharmaceutical Industry 10.4.7 On Commercial
Biorepositories/Banks and Scale of Operations 10.4.8 On
Commercial and Public Biobanking10.4.9 On the Most Attractive
Segment in Commercial Biobanking10.4.10 On Biobanking in
202010.4.11 On Drivers and Challenges in the Sector10.5 Mr Rob
Fannon, Clinical Operations Manager, BioServe10.5.1 On the
Services of BioServe10.5.2 On Main Customers for BioServe10.5.3
On the Importance of Biorepositories in Research and
Industry10.5.4 On Technology Use in Biobanks10.5.5 On Increased
Recognition of Biobanking and Harmonisation of
Samples 10.5.6 On the Use of Biobanks by the
Pharmaceutical Industry 10.5.7 On Commercial
Biorepositories/Banks and Scale of Operations 10.5.8 On
Commercial and Public Biobanking10.5.9 On the Most Attractive
Segment in Commercial Biobanking10.5.10 On Biobanking in
202010.5.11 On Drivers and Challenges in the Sector10.6 Dr
Frans A.L. van der Horst, Chairman, Dutch Collaborative
Biobank10.6.1 On Importance of Biorepositories in Research and
Industry10.6.2 On Increased Recognition of Biobanking and
Harmonisation of Samples 10.6.3 On the Services of Dutch
Collaborative Biobank10.6.4 On Commercial Drivers for
Bio-Repositories/Biobanking Market10.6.5 On Commercial and
Public Biobanking10.6.6 On Sustaining/Recovering Costs10.6.7 On
the Most Attractive Segment in Commercial Biobanking10.6.8 On
Ethical, Legal and Social Issues in Biorepositories/Biobanks

11. Conclusions

11.1 Biobanking for Research and Therapeutics

11.2 Biobanking: The Future for Drug Discovery and Personalised
Medicine

11.3 Commercial Drivers of the Biobanking Market

11.4 The Sector Has Marked Challenges, but Many Opportunities
for Growth

List of TablesTable 2.1 Prominent Population-Based
Biobanks, 2011

Table 2.2 Prominent Disease-Oriented Biobanks, 2011

Table 2.3 Some Guidelines and Recommendations for Biobanks,
2011

Table 2.4 Laws and Regulations for Biobank-Based Research,
Consent Requirements, and Privacy/ Data Protection, 2011

Table 3.1 Some Pharmaceutical and Biotechnology Companies with
In-House Biobanks, 2011

Table 4.1 Prominent Companies in the Automated Liquid Handling
Market, 2011

Table 4.2 Prominent Companies in Ultra-Low Temperature Freezer
Market, 2011

Table 4.3 Prominent LIMS Vendors, 2011

Table 4.4 Prominent Consumables Suppliers for Biobanking, 2011

Table 4.5 Prominent Biorepository Service Providers, 2011

Table 5.1 Estimated Number of Biobanks in Europe, 2011

Table 5.2 Biobanking Market: Grouped Revenue Forecasts,
2010-2016

Table 5.3 Biobanking Market: Grouped Revenue Forecasts,
2017-2022

Table 6.1 Human Tissue Banking Market: Overall Revenue
Forecast, 2010-2016

Table 6.2 Human Tissue Banking Market: Overall Revenue
Forecast, 2017-2022

Table 6.3 Human Tissue Banking Market: Revenue Forecasts by
Type of Biobank, 2010-2016

Table 6.4 Human Tissue Banking Market: Revenue Forecasts by
Type of Biobank, 2017-2022

Table 6.5 Human Tissue Banking Market: Revenue Forecasts for
Leading National Markets, 2010-2016

Table 6.6 Human Tissue Banking Market: Revenue Forecasts for
Leading National Markets, 2017-2022

Table 6.7 Some Leading Companies in the World Biobanking
Market, 2011

Table 6.8 Asterand: Revenue by Segment, 2009 and 2010

Table 6.9 Asterand: Revenue by Geographical Area, 2010

Table 7.1 Stem Cell Banking Market: Overall Revenue Forecast,
2010-2016

Table 7.2 Stem Cell Banking Market: Overall Revenue Forecast,
2017-2022

Table 7.3 Prominent Stem Cell Banks Serving the Research
Community, 2011

Table 7.4 Costs of Various Private Cord Blood Banks Worldwide,
2011

Table 7.5 Private Cord Blood Banking Market: Revenue Forecast,
2010-2016

Table 7.6 Private Cord Blood Banking Market: Revenue Forecast,
2017-2022

Table 7.7 Cord Blood Banking Market: Drivers and Restraints,
2012-2022

Table 7.8 Some Prominent Companies in the Cord Blood Banking
Market, 2011

Table 7.9 Cryo-Cell International Revenue, 2009-2010

Table 7.10 China Cord Blood Corp Revenue and Subscribers,
2009-2010

Table 7.11 Cryo-Save Revenue and Operating Profit, 2009-2010

Table 7.12 Cryo-Save Revenue by Region, 2010

Table 9.1 SWOT Analysis of the Biobanking Market: Strengths and
Weaknesses, 2012-2022

Table 9.2 SWOT Analysis of the Biobanking Market: Opportunities
and Threats, 2012-2022

Table 9.3 Information for a Biobank Donor, 2011

Table 11.1 Human Tissue Biobanking Market by Country, 2010,
2016, 2019 & 2022

List of FiguresFigure 2.1 Main Processes Involved in
Biobanking, 2011

Figure 2.2 Classification of Biobanks, 2011

Figure 3.1 Biobanking and Pharmaceutical Development, 2011

Figure 4.1 Biobanking, Applications and Users, 2011

Figure 4.2 Functions of LIMS, 2011

Figure 5.1 Overall Biobanking Market: Revenue Forecast,
2010-2016

Figure 5.2 Overall Biobanking Market: Revenue Forecast,
2017-2022

Figure 6.1 Human Tissue Banking Market: Overall Revenue
Forecast, 2010-2016

Figure 6.2 Human Tissue Banking Market: Overall Revenue
Forecast, 2017-2022

Figure 6.3 Human Tissue Banking Market: Forecast by Type of
Biobank, 2010-2016

Figure 6.4 Human Tissue Banking Market: Forecast by Type of
Biobank, 2017-2022

Figure 6.5 Human Tissue Banking Market: Share by Type of
Biobank, 2010

Figure 6.6 Human Tissue Banking Market: Share by Type of
Biobank, 2022

Figure 6.7 World and US Human Tissue Banking Markets: Revenue
Forecasts, 2010-2022

Figure 6.8 Japan, EU 5 and Other Leading Human Tissue
Banking Markets: National Revenue Forecasts, 2010-2022

Figure 6.9 Human Tissue Banking: National Market Shares, 2010

Figure 6.10 Human Tissue Banking: National Market Shares, 2016

Figure 6.11 Human Tissue Banking: National Market Shares, 2019

Figure 6.12 Human Tissue Banking: National Market Shares, 2022

Figure 6.13 Commercial Sourcing of Biological Samples, 2011

Figure 6.14 Commercial Banking of Biological Samples, 2011

Figure 6.15 Asterand: Revenues, 2009 & 2010

Figure 6.16 Asterand: Revenue Shares by Region of Destination,
2010

Figure 6.17 Asterand: Revenue Shares by Region of Origin, 2010

Figure 7.1 Stem Cell Banking Market: Revenue Forecast,
2010-2016

Figure 7.2 Stem Cell Banking Market: Revenue Forecast,
2017-2022

Figure 7.3 Twenty-Year Storage Costs at Various Private Cord
Blood Banks Worldwide, 2011

Figure 7.4 Cord Blood Banking Market: Revenue Forecast,
2010-2016

Figure 7.5 Cord Blood Banking Market: Revenue Forecast,
2017-2022

Figure 7.6 Cryo-Cell International Revenue, 2009-2010

Figure 7.7 China Cord Blood Corp Revenue and Subscribers,
2009-2010

Figure 7.8 Cryo-Save Revenue and Operating Profit, 2009-2010

Figure 7.9 Cryo-Save Revenue Shares by Region, 2010

Figure 11.1 Biobanking Market: World Sales Forecast, 2010,
2012, 2016, 2019 & 2022 

Companies ListedAbcellute

Abgene

Adnexus Therapeutics

AFNOR Groupe

AKH Biobank

AlloSource

American National Bioethics Advisory Commission 

American Type Culture Collection

Amgen

Analytical Biological Services

ARCH Venture Partners

Asterand

AstraZeneca

Australasian Biospecimen Network (ABN)

Autoscribe

AXM Pharma 

Bayer-Schering

Beckman Coulter

Beike Biotechnology 

Biobank Ireland Trust

Biobank Japan

Biobanking and Biomolecular Resources Research Infrastructure
(BBMRI) 

BioFortis

Biogen Idec

Biogenea-CellGenea 

BioLife Solutions

Biomatrica

Biopta

BioRep

BioSeek

BioServe

BioStorage LLC

BioStorage Technologies

BrainNet Europe

Caliper LifeSciences

Canadian Partnership for Tomorrow

CARTaGENE

Cellgene Corporation

Cells4Health

Chemagen

China Cord Blood Corp

Chinese Ministry of Health

CLB/Amsterdam Medical Center

CorCell

Cord Blood America

Cord Blood Registry 

CORD:USE (US Public Cord Blood Bank) 

CordLife

Cordon Vital (CBR) 

Coriell Institute for Medical Research

Council of Europe (CoE)

Covance

Cryo Bio System

Cryo-Cell International

Cryometrix

Cryo-Save

Cureline

Cybrdi

Danubian Biobank Foundation

deCODE Genetics

Department of Health (DoH, UK)

Draper Laboratory

Duke University Medical Center

Dutch Collaborative Biobank

EGeen

Eli Lilly

Eolas Biosciences 

Estonian Genome Project

EuroBioBank

European Commission (EC)

European Health Risk Monitoring (EHRM)

European Medicines Agency (EMA/EMEA)

European Union Group on Ethics (EGE)

Fisher BioServices

Fondazione I.R.C.C.S. Istituto Neurologico C. Besta

Food and Drug Administration (US FDA)

Foundation for the National Institutes of Health 

Fundación Istituto Valenciano de Oncología

Fundeni Clinical Institute

Genentech

Generation Scotland

GeneSaver

GeneSys

Genetic Association Information Network (GAIN)

Genizon Biosciences

Genome Quebec Biobank 

GenomEUtwin

Genomic Studies of Latvian Population

GenVault

German Dementia Competence Network

GlaxoSmithKline (GSK)

H. Lee Moffitt Cancer Center and
Research Institute 

Hamilton

Hopital Necker Paris - Necker DNA Bank

Human Tissue Authority (HTA)

Hungarian Biobank

HUNT, Norway

ILSBio LLC

Inbiobank

Inbiomed

Indivumed

INMEGEN

Institut National de la Santé et de la Recherche Médicale
(INSERM)

Integrated BioBank of Luxembourg

International Agency for Research on Cancer (IARC)

International Air Transport Association (IATA)

International Organization for Standardization (ISO)

International Society for Biological and Environmental
Repositories (ISBER)

International Stem Cell Corporation

Kaiser Permanente

KORA-gen

LabVantage Solutions

LabWare

Leiden University Medical Center

LifebankUSA

LifeGene

LifeStem

Malaysian Cohort Project

Matrical Biosciences

Matrix

Medical Research Council (MRC)

Medical University of Gdansk

Merck & Co.

Merck Sharp & Dohme Limited (MSD)

Merck-Serono

Micronic

Millennium (Takeda Oncology Company)

MVE-Chart

National Cancer Institute (NCI)

National DNA Bank (US)

National Human Genome Research Institute (NHGRI)

National Institute of Environmental Health

National Institutes of Health (NIH)

National Public Health Institute 

National Research Ethics Service (NRES) 

NeoCodex

NeoStem

Neuromuscular Bank of Tissues and DNA Samples

New Brunswick Scientific

NEXUS Biosystems

Northwest Regional Development Agency

Novacare Bio-Logistics

Novartis

NUgene Project

Ocimum Biosolutions

Office of Biorepositories and Biospecimen Research (OBBR)

OnCore UK

Organisation for Economic Co-operation and Development (OECD)

OriGene

Oxagen

Pacific Bio-Material Management

PathServe

Perkin Elmer

Pfizer

Pharmagene Laboratories Trustees Limited

Polaris Ventures 

Pop-Gen (University Hospital Schleswig-Holstein)

PrecisionMed

Prevention Genetics

ProMedDx

Promoting Harmonisation of Epidemiological Biobanks
in Europe (PHOEBE)

ProteoGenex

Public Population Projects in Genomics (P3G Consortium)

Qiagen

RAND Corporation

Regenetech

REMP

Reproductive Genetics Institute (RGI)

Research Centre of Vascular
Diseases, University of Milan

Rhode Island BioBank, Brown University

Roche

RTS Life Science

Saga Investments LLC

SampleNavigator Laboratory Automation Systems

Sanofi

SANYO Biomedical

Scottish Government

Seattle Genetics

Sejtbank (Hungarian Cord Blood Bank) 

SeqWright DNA Technology Services

SeraCare Life Sciences

Singapore Tissue Network

StarLIMS

Steelgate

Stem Cell Authority

Stem Cells for Safer Medicine (SC4SM)

Stem Cells Research Forum of India

Stemride International

Taiwan Biobank

Taizhou Biobank

TAP

Tecan

The Automation Partnership

The Sorenson Molecular Genealogy Foundation (SMGF)

Thermo Fisher Scientific

Thermogenesis

Tissue Bank Cryo Center (Bulgaria)

Tissue Solutions

Titan Pharmaceuticals

TotipotentSC

Trinity Biobank

Tumorothèque Necker-Entants Malades

UK Biobank

UK Stem Cell Bank

UmanGenomics

Umeå University

University Hospital Angers

University Medical Center Gent

University of Massachusetts Stem Cell Bank

University of Tuebingen, Department of Medical
Genetics

US Biomax

Västerbotten County Council

ViaCord

Wellcome Trust

Wellcome Trust Case-Control Consortium (WTCCC)

Western Australian Genome Health Project

Wheaton Science International

Wisconsin International Stem Cell (WISC) Bank

World Health Organization (WHO)

Zhejiang Lukou Biotechnology Co 

To order this report:Blood Supply, Tissue Banking and Transplantation
Industry: Biobanking for Medicine: Technology and Market
2012-2022

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

 

Read more from the original source:
Biobanking for Medicine: Technology and Market 2012-2022

12-12-2009 13:45 What are stem cells? - An short educational film by the Irish Stem Cell Foundation Stem cells are master cells of the body — want to learn more? Visit http://www.irishstemcellfoundation.org ISCF is an independent not-for-profit organisation whose primary objective is to educate about stem cells, their basic biology and the research and therapies using them. The Foundation will initially focus on education outreach programs, hoping to address the growing problem of bogus stem cell scams being offered to Irish patients over the internet. The Foundation will also assist the development of Irish policy and legislature in this area of medicine and science, ensuring Ireland is informed. The Foundation consists of a broad range of people including Irish doctors, scientists, patient advocates, educators, bioethicists and other associated parties seeking to expand and develop the Irish public's understanding of stem cells.

See more here:
What are stem cells? How can they be used for medical benefit? - Video

04-02-2010 18:43 (October 6, 2009) Dr. Jill Helms, Associate Professor of Surgery at the Stanford School of Medicine, discusses developments in stem cell research and the future of regenerative medicine. Stanford Mini Med School is a series arranged and directed by Stanford's School of Medicine, and presented by the Stanford Continuing Studies program. Featuring more than thirty distinguished, faculty, scientists and physicians from Stanford's medical school, the series offers students a dynamic introduction to the world of human biology, health and disease, and the groundbreaking changes taking place in medical research and health care. Stanford University http://www.stanford.edu Stanford Continuing Studies http Stanford University Channel on YouTube: http://www.youtube.com

See the rest here:
Stem Cells

Continue reading here:
Cell Society International Hosts its 2nd Annual Clinical Conference in San Diego, CA, to Discuss Clinical Advancements ...

24-01-2012 10:25 On January 17th, 2012, the CIRM Governing Board heard from scientists and a patient about the essential role of genomics in the development of stem cell based therapies.

Read more:
Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video

18-11-2011 14:29 Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan. For further discussion visit http://www.HemOnc101.com

Continue reading here:
Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video

As with umbilical cord blood banking, GeneCell International is at the forefront of the research and the technology developed to process and store stem cells found within the dental pulp. Although most people are familiar with banking cord , few people are aware of the advantages of harvesting stem cells from the dental pulp: •Dental pulp can be obtained unobtrusively as children or adults lose teeth •The stem cells found in dental pulp are non-controversial adult stem cells (mesenchymal stem cells) •Dental pulp stem cells are excellent candidates for regenerative medicine and tissue engineering applications GeneCell International is committed to excellence in cell processing and cryogenically storing your dental pulp stem cells.

View post:
GeneCell International Dental Pulp Stem Cell's Banking Services - Video

Robert Klein, former chair of the California Institute of Regenerative Medicine (CIRM), presented this year's advocacy keynote, addressing the looming black cloud over funding for stem cell research in the US. Klein explained that in a financial downturn, creating long term, big picture investments for donors is absolutely necessary to bring to new treatment modalities to market.

Read more:
2011 Summit: Government

Alan Trounson, PhD and President of the California Institute for Regenerative Medicine, offered a positive and forward looking keynote address. Trounson provided an update on CIRM's translational roadmap to regenerative medicine and outlined their accomplishments with over $300 million in funding for human embryonic stem cell research, adult stem cells, cancer stem cells, reprogrammed stem cells and endogenous stem cells for multiple treatments

Follow this link:
2011 Summit: Keynote Address, CIRM's Translational Roadmap to Stem Cell Cures, Alan Trounson, PhD - Video

Major General James Gilman, Commanding General of the US Army Medical Research and Material Command, outlined the US army's extensive research efforts in stem cell technologies and their mission to discover, develop and translate regenerative medicine. He spoke about the military's desire to partner with academia and industry to generate effective treatments for volume, bone, muscle and tissue injuries and about spinal cord regeneration as the military's biggest challenge and hope.

Original post:
2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video

William Bruyea, host of StemCellTV talks to Michael Werner, co-founder and executive director of Alliance for Regenerative Medicine at the Meeting on the Mesa partnering forum at Sanford Consortium in La Jolla, CA. Michael discusses regenerative medicine, stem cells and development, and stem cell regulation.

Read the original post:
StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video

(First Prize for Technical Achievement in Video 2011) Non-Invasive Assessment of Embryo Viability Using Novel Automated Imaging Technology B. Behr 1, SL Chavez1,2,4, KE Loewke1,4, RA Reijo Pera1,2. 1Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA; 2Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA; 3Department of Mechanical Engineering, Stanford University, Stanford, CA; 4Auxogyn, Inc., Menlo Park, CA.

See original here:
Assessment of Embryo Viability (Auxogyn_ASRM_First Prize) - Video

A bit about this wonderful person Bruce H. Lipton, PhD is an internationally recognized leader in bridging science and spirit. Stem cell biologist, bestselling author of The Biology of Belief and recipient of the 2009 Goi Peace Award, he has been a guest speaker on hundreds of TV and radio shows, as well as keynote presenter for national and international conferences.

Read the rest here:
Bruce Lipton,making the connections part 2 - Video

A bit about this wonderful person Bruce H. Lipton, PhD is an internationally recognized leader in bridging science and spirit. Stem cell biologist, bestselling author of The Biology of Belief and recipient of the 2009 Goi Peace Award, he has been a guest speaker on hundreds of TV and radio shows, as well as keynote presenter for national and international conferences.

More:
Bruce Lipton,making the connections part 1 - Video

This video is a preview of Module 2 in the Stem Cell Fellowship through the American Academy of Anti-Aging Medicine. For more information visit http://www.a4m.com

More here:
A4M Stem Cell Fellowship Module II Preview - Video

Dr. Jordan Pomeroy, from the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the Keck School of Medicine of the University of Southern California, presents his work on the derivation and characterization of new pluripotent stem cell lines for clinical applications.

Originally posted here:
Dr. Jordan Pomeroy discusses xeno-Free Derivation and Maintenance of Pluripotent Cell Lines - Video

(Part 3 of 4) Michael McMaster, PhD, spoke at a seminar about stem cell research and environmental health held on September 30, 2009 at the California Institute for Regenerative Medicine. McMaster summarized the challenges of predictive toxicology and described how he has applied human embryonic stem cells as a model system for studying the toxicological effects of nicotine.

Visit link:
Human Embryonic Stem Cells for Predictive Toxicology - Video